NEUROCRINE BIOSCIENCES INC Impairment of Leasehold
NEUROCRINE BIOSCIENCES INC (NBIX) reported Impairment of Leasehold of $700.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLeasehold · last filed 2025-07-30
- NEUROCRINE BIOSCIENCES INC impairment of leasehold for the quarter ending 2024-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC impairment of leasehold for the quarter ending 2023-09-30 was $0.00.
| Period end | Impairment of Leasehold 3 month | Impairment of Leasehold 6 month | Impairment of Leasehold 9 month |
|---|---|---|---|
| 2025-06-30 | $700.00K 10-Q · filed 2025-07-30 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $14.00M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $14.00M 10-Q · filed 2025-07-30 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |